Legal & General Group
APRE icon

Legal & General Group’s Aprea Therapeutics APRE Stock Holding History

Legal & General Group’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-64
Closed -$6K – 3483
2021
Q1 		$6K Hold
64
– – ﹤0.01% 3457
2020
Q4 		$6K Sell
64
-1
-2% -$476 ﹤0.01% 3417
2020
Q3 		$32K Sell
65
-16
-20% -$8.95K ﹤0.01% 2825
2020
Q2 		$63K Buy
81
+29
+56% +$19K ﹤0.01% 2660
2020
Q1 		$36K Sell
52
-12
-19% -$8.8K ﹤0.01% 2699
2019
Q4 		$59K Buy
+64
New +$35.2K ﹤0.01% 2752

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Legal & General Group's APRE Position: Q2 2021 in Review

Legal & General Group sold out of Aprea Therapeutics (APRE) in Q2 2021, closing a stake of 64 shares — an estimated $6K sold.

Legal & General Group first reported a position in APRE in Q4 2019 and held it in 6 quarters. The position peaked at $63K in Q2 2020. 50 funds tracked by Wall St. Rank hold APRE as of Q2 2021.

  • Legal & General Group reported no remaining Aprea Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 64 Aprea Therapeutics shares in Q2 2021, an estimated $6K.
  • Legal & General Group first reported a position in Aprea Therapeutics in Q4 2019 and held it in 6 quarters.
  • Legal & General Group's Aprea Therapeutics position peaked at $63K in Q2 2020.
  • 50 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.